Novel pyrazinone derivatives
CA 2413002 A1 · Owner: Takaki, Tooru · Inventors: Takaki, Tooru; Hayama, Takashi; Kawanishi, Nobuhiko
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Compounds of the general formula (I) or pharmaceutically acceptable salts or esters thereof; pharmaceutical compositions inhibitors against Cdk4 and/or , Cdk6, or anticancer drugs containing the compounds, the salts or the esters as the active ingredient; and processes for the preparation of them wherein Ar1 is aryl fused to the adjacent pyrazinone ring at its 5- and 6-positions or the like; X is CO or the like; Y is CH or the like; Z is CH or the like; V is CH or the like; Wn is (CH2)n- (wherein n is 0 to 4); R1 is hydrogen optionally substituted lower alkyl, or the like; R2 is hydrogen or the like; R3 and R4 are each independently hydrogen or the like; and R5 and R6 are each …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 28, 2001. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended June 28, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 28, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.